Obinutuzumab for B-cell malignancies.


INTRODUCTION We analyse data for the use of obinutuzumab in the treatment of CD20(+) lymphoproliferative disorders with a focus on chronic lymphocytic leukaemia (CLL). Targeted therapy against CD20 with the mAb rituximab led to significant improvements in survival for patients with B-cell non-Hodgkin lymphoma (NHL) and is the current mainstay of treatment… (More)
DOI: 10.1517/14712598.2014.922535


  • Presentations referencing similar topics